HOUSTON--(BUSINESS WIRE)--Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain and brainstem tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company’s clinical stage products Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
A phase two, single-arm, two-stage, interventional trial was conducted in thirty-nine patients with inoperable brainstem gliomas. A subgroup analysis in eleven patients that were diagnosed with non-diffuse intrinsic pontine glioma (NDIPG) is presented. Data describing the results of treatment of the subgroup of patients diagnosed with pediatric recurrent DIPG were previously published. Overall survival in NDIPG at 1, 5, 10 and 15 years are presented. One NDIPG patient experienced a serious, but reversible Grade 4 hypokalemia. Grade 1 and 2 adverse events, including hypernatremia and somnolence, were also reported and were consistent with those observed in other clinical trials.
The publication entitled, “A Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Gliomas. The Report on Non-Diffuse Intrinsic Pontine Glioma (protocol BT-11),” was published in J Cancer Ther 2015; 6: 334-344. The manuscript also appears in the online version http://dx.doi.org/10.4236/jct.2015.64036.
About Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc. (OTCBB:BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and phase 3 clinical trials, particularly in the treatment of brain tumors and other forms of cancer.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to an ability to use Antineoplastons A10 and AS2-1. Burzynski Research Institute, Inc. does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.